Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
Lancet. 2019.
PMID: 30982686
Clinical Trial.
Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
Al-Batran SE, Hozaeel W, Jäger E.
Al-Batran SE, et al. Among authors: hozaeel w.
Onkologie. 2012;35(9):505-8. doi: 10.1159/000341841. Epub 2012 Aug 17.
Onkologie. 2012.
PMID: 23007148
Item in Clipboard
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).
Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, Hübner A, Burmester M, Koenigsmann M, Wiegand J, Zur Hausen G, Linsse B, Kuhl R, Pauligk C.
Al-Batran SE, et al. Among authors: hozaeel w.
Ann Oncol. 2015 Jun;26(6):1244-1248. doi: 10.1093/annonc/mdv129. Epub 2015 Mar 9.
Ann Oncol. 2015.
PMID: 25755108
Free article.
Item in Clipboard
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A.
Al-Batran SE, et al. Among authors: hozaeel w.
Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22.
Lancet Oncol. 2016.
PMID: 27776843
Clinical Trial.
Item in Clipboard
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Goetze TO, Reichart A, Bankstahl US, Pauligk C, Loose M, Kraus TW, Elshafei M, Bechstein WO, Trojan J, Behrend M, Homann N, Venerito M, Bohle W, Varvenne M, Bolling C, Behringer DM, Kratz-Albers K, Siegler GM, Hozaeel W, Al-Batran SE.
Goetze TO, et al. Among authors: hozaeel w.
Ann Surg Oncol. 2024 Jun;31(6):4073-4083. doi: 10.1245/s10434-024-15011-7. Epub 2024 Mar 8.
Ann Surg Oncol. 2024.
PMID: 38459418
Free PMC article.
Clinical Trial.
Item in Clipboard
ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial.
Goetze TO, Reichart A, Bankstahl US, Pauligk C, Loose M, Kraus TW, Elshafei M, Bechstein WO, Trojan J, Behrend M, Homann N, Venerito M, Bohle W, Varvenne M, Bolling C, Behringer DM, Kratz-Albers K, Siegler GM, Hozaeel W, Al-Batran SE.
Goetze TO, et al. Among authors: hozaeel w.
Ann Surg Oncol. 2024 Jun;31(6):4121-4122. doi: 10.1245/s10434-024-15145-8.
Ann Surg Oncol. 2024.
PMID: 38575722
Clinical Trial.
No abstract available.
Item in Clipboard
Cite
Cite